There is nothing that surprises us in Asarina Pharma’s financials. We are now eyeing the phase 2a readout in menstrual migraine, expected by the end of this quarter.
ANNONS
There is nothing that surprises us in Asarina Pharma’s financials. We are now eyeing the phase 2a readout in menstrual migraine, expected by the end of this quarter.